Trialstirzepatideobstructive sleep apnoeawoolcock instituteclinicaltrials.gov

Australian trial will test tirzepatide head-to-head against CPAP in sleep apnoea

The Woolcock Institute phase 2/3 randomised comparative effectiveness study is listed as not yet recruiting, with an October 1, 2026 start.

By Priya Raman · Science Reporter

Sep 29 08:00 ETSource: ClinicalTrials.gov

The wire

01ClinicalTrials.gov registration NCT07846865 sets up a randomised comparative effectiveness trial of tirzepatide versus positive airway pressure for obstructive sleep apnoea, sponsored by the Woolcock Institute of Medical Research.
02Sleep physicians have lacked direct comparisons between weight-loss pharmacotherapy and CPAP, which suffers poor adherence and high discontinuation.
03The trial is not yet recruiting and enrolment, endpoints and sample size are not given in the listing; results are years away.

From the source

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial
NCT07846865 · PHASE2/PHASE3 · NOT YET RECRUITING · Sponsor: Woolcock Institute of Medical Research · Conditions: Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07846865